| Name | VT107 |
| Description | VT107 is a potent pan-TEAD autopalmitoylation inhibitor. VT-107 can be used in cancer therapy research.[1] |
| In vitro | METHODS: HEK293T cells were treated with 3 μmol/L VT107 for 20 h. After incubation of cells with compounds and alkyne palmitate overnight, the relevant TEAD proteins were immunoprecipitated using specific TEAD antibodies, followed by click chemistry and streptavidin western blot analysis to examine the effects of these compounds on the palmitoylation of endogenous TEAD1, TEAD3, and TEAD4 proteins.
RESULTS VT107 effectively blocked the palmitoylation of endogenous TEAD1 and TEAD3 proteins, and also effectively blocked the palmitoylation of endogenous TEAD4 protein. In addition, VT107 showed a strong inhibitory effect on the proliferation of NF2 mutant/deficient cell lines. [1] |
| In vivo | METHODS: VT107 was administered intravenously or orally at a dose of 10 mg/kg. Blood was drawn from the saphenous vein at designated time points. Compounds were quantified by LC/MS-MS using a QTRAP 6500
RESULTS The bioavailability of VT107 was 55%. The half-life after intravenous administration was 2.7 hours. [1] |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (11.48 mM), Sonication is recommended.
DMSO : 260 mg/mL (597.1 mM), Sonication is recommended.
|
| Keywords | YAP–TEAD | VT-107 | VT107 | VT 107 |
| Inhibitors Related | AICAR | MY-1076 | YAP-TEAD-IN-3 | Verteporfin | DC-TEADin02 | MSC-4106 | Thiostrepton | OPN-9652 | VT104 | alpha-Ionone | MYF-01-37 | Ki16425 |
| Related Compound Libraries | Bioactive Compound Library | Post-Translational Modification Compound Library | Inhibitor Library | Stem Cell Differentiation Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | Anti-Cancer Compound Library | Wnt/Hedgehog/Notch Compound Library | Anti-Cancer Active Compound Library |
United States
